Pharmaceuticals News and Research

RSS

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed, Inc., a clinical-stage pharmaceutical company, today announced financial results for the three months ended March 31, 2011.

16 May 2011

Mylan introduces Bromfenac Ophthalmic Solution for cataract postoperative inflammation treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bromfenac Ophthalmic Solution, 0.09%, based on a development and supply agreement with Coastal Pharmaceuticals.

16 May 2011

Monarch completes Inspire cash tender offer at $5.00 per share

Merck, known as MSD outside the United States and Canada, announced today that Monarch Transaction Corp., its wholly-owned subsidiary, successfully completed the cash tender offer for all of the outstanding shares of common stock of Inspire Pharmaceuticals, Inc., which expired at 12:00 midnight, New York City time, on Thursday, May 12, 2011.

16 May 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced that results from a clinical study evaluating the safety and efficacy of Caldolor Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.

16 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

Counterfeit medications are posing an increasing threat to patients' health worldwide, because they offer high returns and low risks for criminal organizations, the U.N. Office on Drugs and Crime said in a statement on Friday, Agence France-Presse reports.

16 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Global health Product Development Partners consortium select GVK BIO as preferred provider

GVK Biosciences, Asia's leading drug discovery research & development organization announced today that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

Teva signs definitive agreement to acquire Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has signed a definitive agreement to acquire 57% of the shares in privately-held Taiyo Pharmaceutical Industry Co. Ltd. for $460 million in cash paid to private shareholders.

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Cyclobenzaprine HCl ER Capsules and was awarded 180 days of marketing exclusivity.

16 May 2011

Genetic link for depression found: Study

Researchers have for the first time confirmed a specific genetic link to depression, according to new evidence published in the American Journal of Psychiatry on Monday. This finding was made independently by research teams in the UK and US, is expected to lead to a better biological understanding of the condition and eventually to more effective antidepressants.

15 May 2011

Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

The Clinton Health Access Initiative, founded by former President Bill Clinton, with funding from the Bill & Melinda Gates Foundation and the U.K. government, has hired former pharmaceutical company scientists "to tinker with the chemistry used to synthesize a key [HIV] drug, tenofovir" in an effort to reduce "the cost of manufacturing," the Wall Street Journal reports.

13 May 2011

AgenoLAB acquires Roche´s RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

13 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Pharmaceuticals News and Research

EntreMed reports net loss of $2.6 million for first quarter 2011

Mylan introduces Bromfenac Ophthalmic Solution for cataract postoperative inflammation treatment

Monarch completes Inspire cash tender offer at $5.00 per share

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Global health Product Development Partners consortium select GVK BIO as preferred provider

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Teva signs definitive agreement to acquire Taiyo

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

Genetic link for depression found: Study

Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

AgenoLAB acquires Roche´s RTCA Cardio Instrument

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence